Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mice, Inbred C57BL | 7 | 2024 | 196 | 1.190 |
Why?
|
| Muscle, Skeletal | 5 | 2020 | 64 | 1.170 |
Why?
|
| Niacinamide | 1 | 2024 | 5 | 0.890 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 6 | 0.890 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 3 | 0.870 |
Why?
|
| Nicotine | 2 | 2024 | 91 | 0.850 |
Why?
|
| Hypothyroidism | 1 | 2024 | 22 | 0.850 |
Why?
|
| Angiotensin I | 2 | 2020 | 4 | 0.840 |
Why?
|
| Peptide Fragments | 2 | 2020 | 19 | 0.840 |
Why?
|
| Mice | 8 | 2024 | 555 | 0.730 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 10 | 0.700 |
Why?
|
| Autophagy | 1 | 2020 | 11 | 0.700 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 15 | 0.700 |
Why?
|
| Animals | 10 | 2024 | 1369 | 0.690 |
Why?
|
| Male | 6 | 2024 | 2620 | 0.440 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 28 | 0.420 |
Why?
|
| Oxidative Stress | 2 | 2024 | 92 | 0.330 |
Why?
|
| Pregnancy | 3 | 2024 | 417 | 0.280 |
Why?
|
| Muscular Atrophy | 2 | 2017 | 9 | 0.270 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 149 | 0.240 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 1 | 0.220 |
Why?
|
| High Fructose Corn Syrup | 1 | 2024 | 5 | 0.220 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2024 | 5 | 0.220 |
Why?
|
| Glucosides | 1 | 2024 | 6 | 0.220 |
Why?
|
| Bone Density | 1 | 2024 | 16 | 0.220 |
Why?
|
| Vascular Calcification | 1 | 2024 | 10 | 0.220 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 13 | 0.220 |
Why?
|
| Hyperlipidemias | 1 | 2024 | 15 | 0.220 |
Why?
|
| Dextran Sulfate | 1 | 2024 | 2 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 21 | 0.210 |
Why?
|
| Female | 4 | 2024 | 2964 | 0.210 |
Why?
|
| Fatty Liver | 1 | 2024 | 52 | 0.210 |
Why?
|
| Liver | 1 | 2024 | 139 | 0.210 |
Why?
|
| Endoribonucleases | 1 | 2023 | 4 | 0.210 |
Why?
|
| Cell Line | 2 | 2020 | 82 | 0.210 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 10 | 0.210 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 11 | 0.200 |
Why?
|
| Inflammation | 1 | 2024 | 122 | 0.200 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2023 | 46 | 0.200 |
Why?
|
| Congenital Hypothyroidism | 1 | 2021 | 1 | 0.190 |
Why?
|
| Thyroxine | 1 | 2021 | 9 | 0.190 |
Why?
|
| Triiodothyronine | 1 | 2021 | 9 | 0.190 |
Why?
|
| Mutation | 1 | 2021 | 51 | 0.180 |
Why?
|
| Diet, High-Fat | 2 | 2024 | 46 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 9 | 0.180 |
Why?
|
| Cathepsin L | 1 | 2020 | 1 | 0.180 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 3 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 16 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 17 | 0.180 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 35 | 0.180 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 33 | 0.160 |
Why?
|
| Muscular Disorders, Atrophic | 1 | 2017 | 1 | 0.140 |
Why?
|
| Dendrimers | 1 | 2017 | 1 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2016 | 1 | 0.130 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 32 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Apoptosis | 1 | 2016 | 117 | 0.120 |
Why?
|
| Renin-Angiotensin System | 1 | 2015 | 7 | 0.120 |
Why?
|
| Humans | 5 | 2023 | 4931 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2024 | 164 | 0.090 |
Why?
|
| Myosin Heavy Chains | 2 | 2017 | 6 | 0.070 |
Why?
|
| Tripartite Motif Proteins | 2 | 2017 | 2 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2017 | 6 | 0.070 |
Why?
|
| Muscle Proteins | 2 | 2017 | 12 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2016 | 10 | 0.060 |
Why?
|
| Atrophy | 2 | 2016 | 5 | 0.060 |
Why?
|
| Aortic Diseases | 1 | 2024 | 3 | 0.060 |
Why?
|
| Aorta | 1 | 2024 | 16 | 0.060 |
Why?
|
| Lipolysis | 1 | 2023 | 11 | 0.050 |
Why?
|
| Age Factors | 1 | 2024 | 152 | 0.050 |
Why?
|
| Phenotype | 1 | 2023 | 62 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 60 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2023 | 6 | 0.050 |
Why?
|
| Palmitates | 1 | 2023 | 5 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 19 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2021 | 12 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2021 | 1 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 2 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 4 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2021 | 15 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2021 | 12 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 11 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 121 | 0.040 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Static Electricity | 1 | 2017 | 1 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 1 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 3 | 0.030 |
Why?
|
| Immobilization | 1 | 2017 | 4 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 11 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 14 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 3 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2016 | 12 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2016 | 8 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Antioxidants | 1 | 2016 | 28 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2015 | 3 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 44 | 0.030 |
Why?
|
| Fibrosis | 1 | 2015 | 36 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2015 | 63 | 0.030 |
Why?
|